42 research outputs found
Physiopathologica, epidemiologica, clinical and therapeutic aspects of exercise-associated hyponatriemia
Exercise-associated hyponatremia (EAH) is dilutional hyponatremia, a variant
of inappropriate antidiuretic hormone secretion (SIADH), characterized by a plasma
concentration of sodium lower than 135 mEq/L. The prevalence of EAH is common in
endurance (6 hours in duration), in which both
athletes and medical providers need to be aware of risk factors, symptom presentation, and
management. The development of EAH is a combination of excessive water intake,
inadequate suppression of the secretion of the antidiuretic hormone (ADH) (due to non
osmotic stimuli), long race duration, and very high or very low ambient temperatures.
Additional risk factors include female gender, slower race times, and use of nonsteroidal
anti-inflammatory drugs. Signs and symptoms of EAH include nausea, vomiting,
confusion, headache and seizures; it may result in severe clinical conditions associated
with pulmonary and cerebral edema, respiratory failure and death. A rapid diagnosis and
appropriate treatment with a hypertonic saline solution is essential in the severe form to
ensure a positive outcome
Iponatriemia ed esercizio fisico
L’iponatriemia associata ad esercizio fisico (EAH) è una evenienza
degli sport di resistenza che può esitare in gravi manifestazioni cliniche
quali l’edema cerebrale o l’insufficienza respiratoria. L’EAH è
una iponatriemia diluizionale, variante della secrezione inappropriata
di ADH (SIADH), caratterizzata da una concentrazione plasmatica
di sodio inferiore a 135 mEq/l. Il sesso femminile e la durata delle
competizioni si associano a più elevato rischio di iponatremia. L’incidenza
di iponatriemia, infatti, aumenta con la durata dell’attività in
special modo dopo 4-8 ore dall’inizio della gara. Le donne sembrano
presentare un rischio maggiore rispetto agli uomini. I meccanismi
fisiopatologici che ne sono alla base comprendono l’aumentata perdita
di sodio con la sudorazione e l’eccessivo introito di fluidi ipotonici
durante e dopo l’evento sportivo. Nella genesi dell’EAH sembra avere
un ruolo determinante l’inadeguata secrezione di AVP mediata da stimoli
non osmotici, tra i quali l’IL-6. Accorgimenti per la prevenzione
dell’iponatremia comprendono l’educazione degli atleti ad un consumo
adeguato di fluidi e il monitoraggio delle variazioni del peso corporeo.
In seguito all’identificazione dello squilibrio elettrolitico è necessaria
una restrizione idrica e un trattamento con infusione di soluzione
ipertonica al 3% soprattutto nei casi di iponatremia severa. L’efficacia
degli antagonisti dei recettori V2 necessita di ulteriori approfondiment
Marked elevation of transaminases and pancreatic enzymes in severe malnourished male with eating disorder
We report a case of a 45 year old Caucasian malnourished male with an history of eating disorder who developed severe liver and pancreatic damage and multiorgan disfunction. At admission to our department, his body mass index (BMI) was 11.1. Biochemical evaluation showed elevated serum levels of transaminases (AST= 2291 U/L, ALT= 1792 U/L), amylase (3620 U/L), lipase (4102 U/L), CPK= 1370 U/L, LDH= 2082 U/L. No other cause of acute liver and pancreatic damage was evidenced. Haematological disorders (anemia, thrombocytopenia, leukopenia) found on admission seem related to bone marrow hypoplasia and to gelatinous marrow transformation described in severe state of malnutrition. Although a moderate increase in liver and pancreatic enzymes are a common finding in malnourished patients, only a small number of reports describes severe liver injury and multiorgan dysfunction. After a few days of treatment (hydration and nutritional support) a marked decrease of serum transaminases, lipase, amylase, CPK, LDH occurred, despite a transient increase in these levels secondary to refeeding syndrome. The association of chronic malnutrition and a decrease in systemic perfusion may be responsible for multiorgan dysfunction. In our patient the high levels of transaminases and pancreatic enzymes were the most important biochemical abnormalities normalized after refeeding
Relationship between hospital volume and short-term outcomes: A nationwide population-based study including 75,280 rectal cancer surgical procedures
There is growing interest on the potential relationship between hospital volume (HV) and outcomes as it might justify the centralization of care for rectal cancer surgery. From the National Italian Hospital Discharge Dataset, data on 75,280 rectal cancer patients who underwent elective major surgery between 2002 and 2014 were retrieved and analyzed. HV was grouped into tertiles: low-volume performed 1-12, while high-volume hospitals performed 33+ procedures/year. The impact of HV on in-hospital mortality, abdominoperineal resection (APR), 30-day readmission, and length of stay (LOS) was assessed. Risk factors were calculated using multivariate logistic regression. The proportion of procedures performed in low-volume hospitals decreased by 6.7 percent (p<0.001). The rate of in-hospital mortality, APR and 30-day readmission was 1.3%, 16.3%, and 7.2%, respectively, and the median LOS was 13 days. The adjusted risk of in-hospital mortality (OR = 1.49, 95% CI = 1.25-1.78), APR (OR 1.10, 95%CI 1.02-1.19), 30-day readmission (OR 1.49, 95%CI 1.38-1.61), and prolonged LOS (OR 2.29, 95%CI 2.05-2.55) were greater for low-volume hospitals than for high-volume hospitals. This study shows an independent impact of HV procedures on all short-term outcome measures, justifying a policy of centralization for rectal cancer surgery, a process which is underwa
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes
Carriers of single pathogenic variants of the CFTR (cystic fibrosis transmembrane conductance regulator) gene have a higher risk of severe COVID-19 and 14-day death. The machine learning post-Mendelian model pinpointed CFTR as a bidirectional modulator of COVID-19 outcomes. Here, we demonstrate that the rare complex allele [G576V;R668C] is associated with a milder disease via a gain-of-function mechanism. Conversely, CFTR ultra-rare alleles with reduced function are associated with disease severity either alone (dominant disorder) or with another hypomorphic allele in the second chromosome (recessive disorder) with a global residual CFTR activity between 50 to 91%. Furthermore, we characterized novel CFTR complex alleles, including [A238V;F508del], [R74W;D1270N;V201M], [I1027T;F508del], [I506V;D1168G], and simple alleles, including R347C, F1052V, Y625N, I328V, K68E, A309D, A252T, G542*, V562I, R1066H, I506V, I807M, which lead to a reduced CFTR function and thus, to more severe COVID-19. In conclusion, CFTR genetic analysis is an important tool in identifying patients at risk of severe COVID-19
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death
: The clinical manifestations of SARS-CoV-2 infection vary widely among patients, from asymptomatic to life-threatening. Host genetics is one of the factors that contributes to this variability as previously reported by the COVID-19 Host Genetics Initiative (HGI), which identified sixteen loci associated with COVID-19 severity. Herein, we investigated the genetic determinants of COVID-19 mortality, by performing a case-only genome-wide survival analysis, 60 days after infection, of 3904 COVID-19 patients from the GEN-COVID and other European series (EGAS00001005304 study of the COVID-19 HGI). Using imputed genotype data, we carried out a survival analysis using the Cox model adjusted for age, age2, sex, series, time of infection, and the first ten principal components. We observed a genome-wide significant (P-value < 5.0 × 10-8) association of the rs117011822 variant, on chromosome 11, of rs7208524 on chromosome 17, approaching the genome-wide threshold (P-value = 5.19 × 10-8). A total of 113 variants were associated with survival at P-value < 1.0 × 10-5 and most of them regulated the expression of genes involved in immune response (e.g., CD300 and KLR genes), or in lung repair and function (e.g., FGF19 and CDH13). Overall, our results suggest that germline variants may modulate COVID-19 risk of death, possibly through the regulation of gene expression in immune response and lung function pathways